Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 222 | 40 | 177 |
| Samples | 217 | 40 | 173 |
| Peptides | 131 | 25 | 109 |
Function
CCND2 · Cyclin D2
The protein encoded by this gene belongs to the highly conserved cyclin family, whose members are characterized by a dramatic periodicity in protein abundance through the cell cycle. Cyclins function as regulators of CDK kinases. Different cyclins exhibit distinct expression and degradation patterns which contribute to the temporal coordination of each mitotic event. This cyclin forms a complex with CDK4 or CDK6 and functions as a regulatory subunit of the complex, whose activity is required for cell cycle G1/S transition. This protein has been shown to interact with and be involved in the phosphorylation of tumor suppressor protein Rb. Knockout studies of the homologous gene in mouse suggest the essential roles of this gene in ovarian granulosa and germ cell proliferation. High level expression of this gene was observed in ovarian and testicular tumors. Mutations in this gene are associated with megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 3 (MPPH3). [provided by RefSeq, Sep 2014].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000261254 | P30279 | 222 | 131 |
Gene Properties
Recurrent Mutations
All 131 amino-acid changes on canonical ENST00000261254 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in CCND2 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in CCND2 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Oral Cavity Carcinoma | 2/54 4% | 0/0 0% |
| T-Lymphoblastic Leukemia | 1/40 2% | 0/0 0% |
| Acute Myeloid Leukemia | 2/90 2% | 0/0 0% |
| Endometrial Carcinoma | 1/42 2% | 11/612 2% |
| Pheochromocytoma and Paraganglioma | 0/0 0% | 1/71 1% |
| Melanoma | 2/210 1% | 25/1899 1% |
| Germ Cell Tumour | 2/25 8% | 0/169 0% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 7/810 1% |
| Gastric Carcinoma | 2/74 3% | 13/1809 1% |
| Other Blood Cancers | 0/61 0% | 22/2725 1% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 1/133 1% |
| B-Cell Non-Hodgkins Lymphoma | 0/88 0% | 19/2534 1% |
| Esophageal Carcinoma | 1/23 4% | 4/769 1% |
| Non-Small Cell Lung Carcinoma | 4/304 1% | 5/1390 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 4/752 1% |
| Other Solid Cancers | 1/94 1% | 7/1515 0% |
| Glioma | 2/52 4% | 8/2127 0% |
| Medulloblastoma | 0/0 0% | 2/450 0% |
| Colorectal Carcinoma | 8/143 6% | 7/3239 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 11/2550 0% |
| Bladder Carcinoma | 0/58 0% | 3/956 0% |
| Plasma Cell Myeloma | 1/44 2% | 0/305 0% |
| Hepatocellular Carcinoma | 0/46 0% | 6/2210 0% |
| Neuroendocrine Tumour | 2/154 1% | 0/577 0% |
| Head and Neck Carcinoma | 2/85 2% | 2/1574 0% |
| Neuroblastoma | 3/87 3% | 0/1331 0% |
| Ovarian Carcinoma | 0/109 0% | 2/998 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 3/1592 0% |
| Breast Carcinoma | 1/144 1% | 4/3264 0% |
| Kidney Carcinoma | 1/85 1% | 2/1862 0% |
Mutation Distribution
Where CCND2 is mutated · all tissues, split by cell line vs tissue
How many mutations in CCND2 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 222 mutations in CCND2
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|